ARQL News and Press, ArQule Inc. From 08/05/19

ArQule, Inc. (Nasdaq:ARQL) today announced that Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St. Regis New York in New York City. About ArQule ArQule is a biopharm...

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019 at 9:00 a...

ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a genera...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...

ArQule (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, recently closed its underwritten public offering of 10,637,500 shares of common stock, which includes 1,387,500 shares representing the over-a...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Shares of ArQule ( ARQL ) have risen by over 50% since my last update piece stated it remained a Buy with substantial upside ahead over the long term. Readers may be tempted to take full profits on the name considering the high appreciation that's taken place recently. However, when thesis str...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...